By Sheeba M. | May 13, 2026
Cannabis Tax Reform Could Unlock $1.5B in MSO Savings — Here’s Who Wins
The cannabis industry has endured one structural headwind for 15 years: IRS Section 280E, which prohibits cannabis businesses from deducting ordinary operating expenses. Multi-state operators have paid effective tax rates of 35-40% because of this single rule. Now, that’s about to change.
Federal tax reform discussions happening on Capitol Hill right now include carve-outs specifically designed to remove 280E deductions for cannabis operators post-Schedule III reclassification. Here’s what it means for your portfolio.
The Math: $1.5B in Sector-Wide Savings
Curaleaf alone operates at roughly $3.2B in annual revenue with EBITDA margins of 28%. Under current 280E constraints, the company pays approximately $300M annually in excess taxes. Removal of 280E would cut that burden in half, adding an estimated $150M to annual cash flow.
Cresco Labs and Green Thumb Industries face similar dynamics—each could see $80-120M in annual tax relief under Schedule III. For smaller players like Verano, the math translates to roughly $30-50M in freed-up capital annually.
Aggregate impact: At $1.5B in tax relief across the top 10 MSOs, we’re looking at a 15-20% valuation multiple expansion, assuming equities trade on a 10-12x EBITDA multiple post-reform. That’s potentially $3-4 per share upside for the mid-caps.
The Timing: Q4 2026 Is the Critical Window
Tax reform typically moves slowly, but cannabis has become a bipartisan issue. Both Democrats and Republicans see tax relief for MSOs as a way to accelerate federal rescheduling without direct re-legalization legislation. Expect final language on 280E removal to surface by September 2026, with effective dates in Q4.
Canadian LPs like Canopy Growth and Tilray won’t benefit directly, but the tax relief for U.S. operators will accelerate M&A consolidation in the sector—positioning Canadian players for acquisition as strategic assets.
Why This Matters Now
The removal of Section 280E deductions is the single largest profitability inflection point still left in cannabis finance. Unlike state-level legalization (which is incremental), this is a structural change to MSO economics. Once it’s formalized, the mid-caps become genuinely profitable on a cash basis—not just an EBITDA story.
For equity investors, this is the “all clear” signal you’ve been waiting for. The sector’s last major structural headwind is about to be removed.
Sources
- U.S. Senate — Cannabis Tax Reform Discussion Draft — Current legislative framework on 280E removal
- IRS Publication 535 — Business Expenses — Section 280E deduction details
- Curaleaf 10-Q Filing — Tax expense detail — Real MSO tax burden documentation
Track cannabis stocks with the Weedstock Real-Time Tracker